301239.SZ
普瑞眼科
SZSE · Q 卫生 · CN
CNY 35.29
+0.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.9B | 2.8B | 2.7B | 2.7B | 1.7B |
| Cost of Revenue | 1.8B | 1.8B | 1.7B | 1.5B | 1.0B |
| Gross Profit | 1.0B | 1.0B | 990.4M | 1.2B | 719.1M |
| Operating Expenses | |||||
| R&D Expense | 10.8M | 10.8M | 8.0M | 11.0M | 6.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 316.9M | 329.6M | 383.5M | 364.8M | 270.3M |
| Selling & Marketing Expense | 533.7M | 518.4M | 500.6M | 448.6M | 343.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 956.3M | 953.4M | 986.0M | 895.5M | 671.2M |
| Cost and Expenses | 2.8B | 2.7B | 2.7B | 2.4B | 1.7B |
| Operating Income (EBIT) | 71.6M | 31.1M | 7.1M | 386.0M | 67.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 53.1M | 12.5M | (26.0M) | 362.2M | 59.2M |
| Income Tax Expense | 62.6M | 66.2M | 66.8M | 84.2M | 38.7M |
| Bottom Line | |||||
| Net Income | (17.6M) | (60.9M) | (101.9M) | 267.9M | 20.6M |
| Earnings from Cont. Ops | (9.5M) | (53.7M) | (92.8M) | 278.0M | 20.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (17.6M) | (60.9M) | (101.9M) | 267.9M | 20.6M |
| Per Share | |||||
| Basic EPS | (CN¥0.12) | (CN¥0.41) | (CN¥0.68) | CN¥1.79 | CN¥0.16 |
| Diluted EPS | (CN¥0.12) | (CN¥0.41) | (CN¥0.68) | CN¥1.79 | CN¥0.16 |
| Revenue Per Share | CN¥19.13 | CN¥18.83 | CN¥17.88 | CN¥18.16 | CN¥13.42 |
| Shares | |||||
| Basic Shares Outstanding | 150.3M | 148.6M | 149.8M | 149.7M | 128.6M |
| Diluted Shares Outstanding | 150.3M | 148.6M | 149.8M | 149.7M | 128.6M |
| Profitability Metrics | |||||
| EBITDA | — | 267.9M | 215.1M | 546.1M | 189.4M |
| D&A | — | 236.8M | 208.0M | 160.1M | 121.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026